JOINT FILING AGREEMENTJoint Filing Agreement • March 30th, 2017 • Miller Courtlandt G • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons who executes a copy of this Joint Filing Agreement agrees to the joint filing on behalf of each of them of a Statement on Schedule 13D relating to securities of Provectus Biopharmaceuticals, Inc., and of amendments to that Schedule 13D, and agrees to the filing of this Joint Filing Agreement as an exhibit to the Schedule 13D.
AMENDED INVESTMENT AGREEMENTAmended Investment Agreement • March 30th, 2017 • Miller Courtlandt G • Pharmaceutical preparations • Delaware
This is an amended and restated agreement (this “Amended Agreement”) among each of the persons (each an “Investor,” and together the “Investors”) who signs a signature page to this Amended Agreement (a “Signature Page”) regarding the terms on which each of the Investors agrees that, upon fulfillment of certain conditions, it will purchase Units consisting of Series D Preferred Stock (“Series D Stock”) and common stock (“Common Stock”) of Provectus Biopharmaceuticals, Inc. (“Provectus”), a Delaware corporation.
